DFAC vs IBB
Dimensional US Core Equity 2 ETF vs iShares Biotechnology ETF
- • DFAC has the lower expense ratio at 0.18% vs 0.44% for IBB.
Side-by-side metrics
| Metric | DFAC | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.18% | 0.44% |
Dividend yield Trailing 12-month yield. | — | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $87.72B | $11.50B |
YTD return | 13.31% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.94 | 0.60 |
P/E ratio | 21.44 | 25.48 |
Last price | $45.22 | $217.75 |
Inception | — | — |
Issuer | Dimensional | iShares |
DFAC top holdings
| NVDA | NVIDIA Corp | 5.99% |
| AAPL | Apple Inc | 5.76% |
| MSFT | Microsoft Corp | 4.57% |
| META | Meta Platforms Inc Class A | 2.22% |
| AMZN | Amazon.com Inc | 2.03% |
| GOOGL | Alphabet Inc Class A | 1.74% |
| GOOG | Alphabet Inc Class C | 1.24% |
| JPM | JPMorgan Chase & Co | 1.22% |
| MU | Micron Technology Inc | 1.13% |
| AVGO | Broadcom Inc | 1.09% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About DFAC
DFAC (Dimensional US Core Equity 2 ETF) is Broad US equity market with small and value tilts. Managed by Dimensional, the fund carries $87.7B in assets under management, an expense ratio of 0.18%. Its largest holding is NVIDIA Corp (NVDA), which represents 6.0% of the portfolio. Real Estate is the fund's largest sector exposure at 0.2%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.